In major shake-up, Novartis combines pharma, oncology units, leaving cancer commercial head, CMO out of job
Novartis CEO Vas Narasimhan is giving the Swiss pharma a huge makeover even ahead of a possible spinoff of generics unit Sandoz, pushing out three C-level executives ...
Continue Reading →
